Viridian Therapeutics Earns “Buy” Rating from Needham & Company LLC.

Viridian Therapeutics (NASDAQ: VRDN) received a "Buy" rating from Needham & Company LLC, along with a $30 target price, according to a research note on Wednesday. Other firms have also issued research reports on the stock, with Oppenheimer increasing their target price to $36 and HC Wainwright setting a $37 target. Royal Bank of Canada and Wedbush also reaffirmed "outperform" ratings for the company.

March 23, 2024
3 Articles